Clinical characteristics and prognosis of 46 patients with macrofocal multiple myeloma
10.3760/cma.j.cn112138-20210908-00626
- VernacularTitle:46例巨灶型多发性骨髓瘤患者临床特征及预后分析
- Author:
Wenqiang YAN
1
;
Huishou FAN
;
Jingyu XU
;
Jiahui LIU
;
Chenxing DU
;
Shuhui DENG
;
Weiwei SUI
;
Yan XU
;
Lugui QIU
;
Gang AN
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所）实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室，天津 300020
- Keywords:
Multiple myeloma;
Plasmacytoma;
Prognosis;
Osteolysis
- From:
Chinese Journal of Internal Medicine
2022;61(7):801-805
- CountryChina
- Language:Chinese
-
Abstract:
The clinical characteristics, laboratory results, response to treatment, and prognosis of 46 macrofocal multiple myeloma(MFMM) patients at our center from January 2013 to December 2019 were analyzed retrospectively. The other 92 patients were selected as matched-controls based on diagnostic period and treatment. Among the 1 137 MM patients, 46 patients met the definition criteria of MFMM (4.0%), with median age 56 years, which was not statistically different from whole MM population ( P=0.066). According to the international staging system (ISS) and Revised ISS, the proportion of patients with advanced stage in MFMM group was less common than that of controls ( P<0.05). More plasmacytomas in MFMM patients were presented (43.5% vs. 18.5%, P<0.05). Regarding cytogenetic abnormalities, there were minor patients manifesting high-risk features in MFMM group (15.8% vs. 32.2%, P=0.058). Translocation(11;14) could be detected in 32.4% MFMM patients and 9.4% typical myeloma patients ( P<0.05). The treatment regimens were comparable. As to the best response of treatment, the complete response (CR) rate in MFMM group was significantly higher than that of controls (78.3% vs. 60.9%, P<0.05). The median follow-up time was 37.9 months. The median progression-free survival in MFMM and control groups were 77.5 vs. 39.8 months, respectively ( P<0.05). The overall survival (OS) of MFMM patients was significantly longer (not reached vs. 68.2 months, P<0.05).
